Compare Amphastar Pharmaceuticals Inc (AMPH) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Futu Holdings Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Futu Holdings Ltd trades at $105.88 (market cap $15.24B). The key difference: Futu Holdings Ltd is far larger — about 17.6× Amphastar Pharmaceuticals Inc's market cap, and Futu Holdings Ltd pays a 2.39% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FUTU | |
|---|---|---|
Market Cap | $863.95M | $15.24B |
Sector | Health | Financials |
52-Week High | $30.81 | $199.04 |
52-Week Low | $16.87 | $89.76 |
Enterprise Value | $1.26B | $15.09B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Futu Holdings Limited (FUTU) trades at $109.02, up 4.31% today, with a bullish technical signal from moving averages and strong support at $106. The company reported robust 2025 revenue of $22.85 billion and net income of $11.34 billion, with a high net margin of 49.62%. Valuation ratios appear reasonable, with a P/E of 12.07 and P/S of 5.05. However, recent earnings misses in Q1 2026 and a securities class action lawsuit deadline on August 25, 2026, introduce near-term uncertainty.
The outlook for FUTU is mixed: strong profitability and analyst buy ratings (58% consensus) support upside, but legal risks and earnings volatility pose challenges. Investors should weigh solid fundamentals against regulatory and litigation headwinds, with technical levels suggesting $111 as immediate resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
